{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006668","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.929690+00:00","generated_at":"2026-06-09T01:19:51.763766+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celldex Q3 net loss $38.3M ($0.81/shr); Phase 2 CSU enrollment complete, data by YE 2023","bullets":["Net loss of $38.3M ($0.81 per share) vs $26.8M ($0.57) a year ago; revenue $1.5M.","Cash, equivalents and marketable securities $235.3M, sufficient to fund operations through 2025.","Phase 2 CSU study (n=208) enrollment complete; topline data expected by end of 2023.","Phase 1b prurigo nodularis data accepted for oral presentation at World Congress on Itch (Nov 5-7).","Phase 2 studies in CIndU, EoE ongoing; Phase 2 PN study planned for early 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006668","json":"https://secwatch.observer/filing/0001171843-23-006668.json","markdown":"https://secwatch.observer/filing/0001171843-23-006668.md","text":"https://secwatch.observer/filing/0001171843-23-006668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000117184323006668/0001171843-23-006668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000117184323006668/f8k_110223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T01:19:51.763766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5625ea3a557aa6eb7c04a5bd09ef775d907af15f","claim":"Celldex Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $1.5 million.","evidence_excerpt":"activities of $19.0 million for the three months ended September 30, 2023. At September 30, 2023, Celldex had 47.3 million shares outstanding. Revenues: Total revenue was $1.5 million in the third quarter of 2023 and $2.8 million for the nine months ended September 30, 2023, compared to $0.4 million and $0.7 million for the comparable periods in 2022. The","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/744218/000117184323006668/0001171843-23-006668-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$1.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}